
EU Approves AbbVie’s Maviret for Acute Hepatitis C Treatment
The European Commission has cleared AbbVie’s antiviral therapy Maviret for the treatment of acute hepatitis C in adults and children aged three and older. This decision marks a shift in clinical strategy, allowing healthcare providers to initiate curative treatment immediately upon diagnosis rather than waiting for the infection to become chronic.























